Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04162756 Approved for marketing - Clinical trials for Relapse/Refractory Mantle Cell Lymphoma

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

ZUMA-18
Start date: n/a
Phase:
Study type: Expanded Access

The primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially available Cohort 2: To provide access to KTE-X19 for individuals with r/r MCL whose commercially manufactured product did not meet commercial release specification(s)

NCT ID: NCT01833039 Approved for marketing - Clinical trials for Relapsed or Refractory Mantle Cell Lymphoma

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.